ArticleScientific reports2025
Estimated burden of serious mycoses in Poland.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poland, with a population of 38 million, lacks a comprehensive dataset on major fungal infections, leaving the country absent from international fungal burden maps. This study provides a comprehensive analysis of databases of published literature and national demographic and health data to estimate the incidence and prevalence of serious fungal infections in Poland, focusing on the general population and high-risk groups. The estimates indicate a substantial and heterogeneous burden of serious mycoses in Poland. The most common yeast infection is recurrent vulvovaginal candidosis, affecting 12,300-81,600 women annually, while invasive candidosis leads to 280-4600 cases of candidaemia, mostly in intensive care units. Cryptococcosis is very rare, with about 30 cases per year, and Pneumocystis pneumonia occurs in 53-959 patients annually. Invasive aspergillosis, with about 5000 estimated cases annually, is the most important mould infection, mainly affecting patients with respiratory disease and immunosuppression. Chronic pulmonary aspergillosis adds about 3,200 cases each year. Mucormycosis is estimated at around 60 cases annually. Other mycoses, such as keratitis and subcutaneous forms, are reported only sporadically. These findings highlight that serious mycoses are a relevant but under-recognized health problem in Poland and underline the need for improved surveillance and targeted public health measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.